Status:
RECRUITING
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Lead Sponsor:
Ting YANG
Conditions:
Primary Central Nervous System Lymphoma (PCNSL)
Diffuse Large B-Cell Lymphoma
Eligibility:
All Genders
18-75 years
Brief Summary
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients ...
Eligibility Criteria
Inclusion
- Aged between 18 and 75 years.
- The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.
- Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.
- Case group patients must have complete supporting imaging and pathology data.
Exclusion
- Presence of other systemic malignancies.
- Presence of severe infections or metabolic disorders.
- Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.
- Pregnant or lactating women.
- Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure).
- Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.
Key Trial Info
Start Date :
March 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07188077
Start Date
March 1 2025
End Date
March 1 2027
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China